Objective: To determine which vascular pathology measure most strongly correlates with white matter hyperintensity (WMH) accumulation over time, and whether Alzheimer disease (AD) neuropathology correlates with WMH accumulation.
Results: Mean age at death was 94.5 years (5.5 SD). In the final mixed-effects models, arteriolosclerosis, myelin pallor, and Braak score remained significantly associated with increased WMH accumulation over time. In post hoc analysis, we found that those with Braak score 5 or 6 were more likely to also have high atherosclerosis present compared with those with Braak score 1 or 2 (p 5 0.003).
Conclusion:
Accumulating white matter changes in advanced age are likely driven by small-vessel ischemic disease. Additionally, these results suggest a link between AD pathology and white matter integrity disruption. This may be due to wallerian degeneration secondary to neurodegenerative changes. Alternatively, a shared mechanism, for example ischemia, may lead to both vascular brain injury and neurodegenerative changes of AD. The observed correlation between atherosclerosis and AD pathology supports the latter. Disruption of white matter integrity, frequently observed as white matter hyperintensities (WMH) on T2-weighted MRI sequences, has detrimental effects on cognitive function, motor performance, and functional status in the elderly [1] [2] [3] and is associated with increased risk of all types of dementia, including Alzheimer disease (AD). 4 Furthermore, WMH accumulation over time has been shown to increase risk of cognitive decline. 3, [5] [6] [7] While the general consensus is that the etiology of white matter accumulation is secondary to small-vessel ischemic changes, [8] [9] [10] [11] [12] [13] it is not well established whether those with faster WMH accumulation may have contributions from other pathologies. Because accumulation of WMH increases risk of cognitive decline, identifying the pathologic correlates of faster WMH accumulation could potentially guide interventions targeting specific risks for prevention and treatment to preserve cognitive function in the elderly. Furthermore, while there are previous observations supporting a link between cerebrovascular disease (CVD) and AD, 14 it is not clearly established whether WMH progression is associated with neurodegenerative changes of AD. Thus, our aim was to better understand whether small-vessel ischemic disease is the sole contributor to global WMH progression or whether there is any contribution from neurodegenerative disease. To our knowledge, there are few, if any, other studies examining the association between longitudinal changes in global WMH and pathologic findings measured after death. We hypothesized that accumulation of WMH lesions measured on serial MRI scans would be associated with measures of small-vessel ischemic disease and AD pathology.
METHODS Participants. Participants were community-dwelling healthy older adults from the Oregon Brain Aging Study. 15 Study inclusion and exclusion criteria and measurement methods have been described previously. 16 Initially, healthy older persons with no medical comorbidities were enrolled. Later, to better represent the population, subjects with well-controlled, chronic medical conditions were also enrolled. Of the 375 volunteers evaluated between 1989 and 2005, 305 met inclusion criteria and were enrolled. Attrition rates caused by loss to follow-up other than death were ,1% per year.
Standard protocol approvals, registrations, and patient consents. The Portland Veterans Affairs Medical Center and Oregon Health & Science University Institutional Review Boards (IRBs) approved the study (IRB nos. 00002 and 361). Volunteers signed written informed consent.
Participant assessments. Volunteers were examined every 6 months with the Mini-Mental State Examination 17 and Clinical Dementia Rating (CDR) scale. 18 A detailed battery of neuropsychological tests, 15 Cognistat, 19 neurologic examination, and brain MRI scans 20 were performed annually. APOE was genotyped in all volunteers using standard methods. Established clinical criteria were used to make diagnoses of possible or probable AD, vascular dementia, and mixed dementia. 21, 22 Mild cognitive impairment was defined as a CDR 5 0.5 and not meeting diagnostic criteria for dementia. Cognitive impairment (CI) was defined as having a CDR .0 at death, and no CI defined as CDR 5 0 at death.
Participant inclusion and exclusion criteria. Autopsy was performed on 125 of the 193 participants who died. Of the 125, 71 met inclusion for this study for having 1) $2 WMH volumes measured, 2) last MRI ,36 months before death, and 3) last cognitive evaluation ,24 months before death. Five subjects were excluded for WMH volumes that were .3 SD than the mean of the entire group at baseline or not having brain tissue available for reexamination, leaving 66 participants.
MRI acquisition. Images were acquired with a 1.5-tesla magnet.
The protocol consisted of continuous-slice, multiecho, multiplanar image acquisition, with 4-mm-thick coronal slices and a 24-cm 2 field of view using a 256 3 256 acquisition matrix with the following pulse sequences: 1) T1-weighted sagittal images (repetition time [TR] 5 600 milliseconds, echo time [TE] 5 20 milliseconds); and 2) multiecho sequence T2-weighted (TR 5 2,800 milliseconds, TE 5 80 milliseconds) and proton density (TR 5 2,800 milliseconds, TE 5 32 milliseconds) coronal images perpendicular to the sagittal plane.
MRI analysis. Analysts were blinded to clinical and previous imaging data. An imaging software, REGION, was used to quantitatively assess regional brain volumes of interest. 20 Tissue types on each coronal image were separated using recursive regression analysis of bi-feature space based on relative tissue intensities. Pixel areas were summed for all slices and converted to volumetric measures by multiplying by the slice thickness for the region of interest. Using REGION's sampling tools, the analysts selected representative, unambiguous pixels of WMH (as well as brain tissue, fluid, and bone) from the multiecho sequence display. WMH was distinguished from brain tissue and fluid based on higher signal on both the proton density and T2 images. 16 The main outcome of this study was total WMH volume (cm 3 ), which included both subcortical and periventricular WMH. Median number of MRIs was 4.
Pathologic assessments. Braak and Consortium to Establish a
Registry for Alzheimer's Disease systems were used to stage neurofibrillary tangles (NFTs) and neuritic plaques (NPs). 23, 24 As described previously, brains were examined grossly and microscopically after fixation in neutral-buffered formaldehyde solution for 2 weeks. 25 Samples from bilateral cortical lobes, frontal lobe white matter, anterior cingulate gyrus, hippocampus, amygdala, bilateral striatum and thalamus, midbrain, pons, medulla, and cerebellum were evaluated microscopically. Hematoxylin & eosin with Luxol fast blue stain was used to stain myelin on 6-mm sections from all regions. An occipital cortical section was stained with Congo red-gallocyanin for amyloid angiopathy. A modified Bielschowsky silver impregnation method was used to identify diffuse plaques and NPs. Selected sections of the hippocampus and neocortical regions were immunostained with antibody to tau (tau2; Sigma, St. Louis, MO). Lewy bodies were assessed for histologically in the midbrain and nucleus locus coeruleus by evaluation of hematoxylin & eosin/Luxol fast blue-stained sections and by anti-a-synuclein immunohistochemistry (antibody from Novus Biologicals, Littleton, CO) performed on sections of amygdala and frontal cortex. Each subject underwent additional detailed assessments for CVD and vascular brain injury. Presence of lacunar infarcts and large-vessel strokes was evaluated by visual inspection and microscopic examination bilaterally. Because acute or subacute infarcts close to death were more likely to have occurred after a subject's last MRI scan, only more remote infarcts were considered for this study. Myelin pallor was graded in the frontal white matter. The frontal watershed area is 1 of the 2 areas recommended by the National Institute on Aging-Alzheimer's Association guidelines for neuropathologic assessment for CVD. 26 In addition, previous studies have shown progression of WMH to be greatest in the anterior white matter. 27 Additional sections from the deep gray nuclei, caudate head (from the anterior portion of the caudate away from the ventricle), the putamen and globus pallidus (at the level of the anterior commissure), and from the midlevel of the thalamus were examined for arteriolosclerosis and microvascular disease. We defined microvascular disease as microscopic lesions attributed to ischemia, ranging from foci of pallor to neuronal loss, and gliosis without a requirement of frank tissue infarction. Microinfarcts were defined as lesions with neuronal loss and gliosis. Remote tissue necrosis distinguished microinfarcts from milder microvascular lesions. Arteriolosclerosis was defined as thickening of the walls and narrowing of the lumens of small arteries and arterioles. Most arteriolosclerosis observed in evaluated cases was hyaline in nature. Atherosclerosis was established by gross examination of the brain, and defined as thickening of the arteries of the brain through deposition of fatty material. Arteriolosclerosis, atherosclerosis, microvascular disease, myelin pallor, and amyloid angiopathy were rated as none, mild, moderate, or severe by a neuropathologist blinded to clinical data.
Statistical analyses. Pearson x

2
, Fisher exact test, or t tests were used as appropriate to compare subject characteristics between clinical diagnostic categories (CI vs no CI). WMH volume was logtransformed to obtain a normal distribution. To identify variables to be included in the final models, first each pathologic variable was included in separate models. The pathologic measures included in each analysis were NFT Braak stage (0, 1, or 2 vs 3 or 4 vs 5 or 6) and NP category (none or mild vs moderate or severe), presence of microinfarcts, lacunar infarcts, large-vessel infarcts, amyloid angiopathy, and low vs high groups for arteriolosclerosis, microvascular disease, atherosclerosis, and myelin pallor. Individual mixed-effects models, which allow random intercept and age slope, with WMH volume as the outcome, were run for each pathologic measure with a time variable (age at each MRI assessment), adjusting for intracranial volume. A final model was created for variables that had a p value ,0.1. Analyses were performed with and without adjusting for age at death, duration of follow-up (time from first MRI to death), and APOE status as potential confounders. In secondary analyses, we examined the impact of clinical diagnosis on our final model. Diagnosis before death and diagnosis at each MRI time point as a timevarying covariate were included in the final model. Additionally, in post hoc analysis, independent univariate analyses, using Pearson x 2 or Fisher exact tests, examined the associations between AD and CVD pathology. JKMP version 5.0.1a and SAS version 9.2 (SAS Institute, Cary, NC) were used for statistical analyses.
RESULTS
Of the 66 subjects, all of whom had no CI at entry, 42 died with CI (table 1) figure) . Overall, a 1-year increase in age was associated with a 3% increase in WMH volume. Those with a high degree of arteriolosclerosis had, on average, a 5% larger (table 3) . Those with one or more APOE e4 alleles had on average 4% more WMH accumulation annually compared with those without the e4 allele. Findings did not change when adjusted for duration of follow-up and age at death. No other significant associations were observed. DISCUSSION Our results suggest that arteriolosclerosis is the strongest pathologic correlate of accumulating WMH in aging. This finding is consistent with previous cross-sectional observations demonstrating that smallvessel ischemic disease is one of the main causes of age-associated white matter integrity disruption. [8] [9] [10] [11] [12] [13] One such recent cross-sectional study examined the pathologic correlates of white matter lesion burden in 93 research participants and found that arteriolosclerosis, when examined alone, was very strongly correlated with WMH volume. 28 Equally important, we found that the presence of more extensive NFT pathology (higher Braak stage) is associated with more WMH accumulation over time in very old individuals. There may be a number of plausible explanations for this association. First, wallerian degeneration of the myelinated axons, secondary to the neuronal damage due to NFTs, may lead to white matter disruption that appears as WMH on MRI scans. 29 Second, ischemic injury to the axons, manifested as white matter changes on imaging, may eventually lead to tangle formation and neuronal degeneration. There is some indirect evidence from traumatic brain injury research that axonal injury may cause disorganization of the axonal cytoskeleton ultimately triggering tau phosphorylation and aggregation. 30 Another plausible mechanism by which NFTs are correlated with white matter changes may be that there is a common mechanism leading to both. In this scenario, ischemia may lead to both changes in the white matter as well as trigger processes that lead to neurodegeneration of AD. 31 For example, reduced cerebral blood flow in animal models leads to accumulation of amyloid-b oligomers, and increases both neuronal amyloid-b levels and neuronal tau phosphorylation. [32] [33] [34] Observational studies in humans also suggest an association between CVD risk factors and AD clinical diagnosis, as well as neuropathologic changes of AD. 35 Further supporting the view that ischemia may lead to NFTs in old age, we found that those with high levels of atherosclerosis had more NFTs. This finding replicates previous observations. A recent autopsy study examined the frequency and severity of cerebral atherosclerosis in 1,000 subjects, 410 with AD, 531 with other neurodegenerative diseases (synucleinopathies, TDP-43 [TAR DNA-binding protein 43] proteinopathies, tauopathies), and 59 normal aging subjects. The authors found that the AD group had a significantly higher percentage of individuals with atherosclerosis (77%) compared with normal subjects (47%) or those with other neurodegenerative diseases (43%-67%). Atherosclerosis ratings were highly correlated with NP, NFT, and cerebral amyloid angiopathy ratings in the whole sample and within individual groups. 36 Another study examined the correlation between CVD and AD pathology in 1,054 subjects from the National Alzheimer's Coordinating Center database, and found a strong correlation between atherosclerosis and increased frequency of NPs. 37 Both of these studies have found a correlation between atherosclerosis and the neurodegenerative changes of AD. Whereas we found a correlation between atherosclerosis and NFTs, we did not find a correlation between atherosclerosis and NPs. This may be attributable to our relatively small sample size. Similarly, we also did not observe a correlation between atherosclerosis and WMH.
This study has some other limitations. Participants came from a well-described cohort of relatively healthy, mostly Caucasian individuals who were very old, limiting Analyses are adjusted for intracranial volume. The results are similar when further adjusting for age at death and duration of follow-up.
its generalizability to younger cohorts. Our study experienced the common challenges of longitudinal research spanning decades whereby changes in technologies and protocols inevitably occur. To ensure consistency of assessment and analysis of pathologic and imaging data, we retained the same methodology over 2 decades. As a result, the number and types of pathologic measures that we could include were limited. Similarly, because of the spatial resolution of a 1.5-tesla magnet MRI scanner, small regions of pathology may have been missed. Furthermore, our sample size was limited to 66 individuals. All of these limitations may have contributed to a lack of relationship found for a number of pathologic variables. A final limitation is that assessment of our outcome, MRI WMH accumulation, occurred before the autopsy at which time the independent variables including pathologic measures were obtained. Future studies using in vivo methods to measure tau and amyloid burden, vascular integrity, and blood flow, to correlate with changes in WMH in larger populations, are needed to validate our findings. Despite these limitations, to our knowledge, ours is one of the few imaging-pathologic correlation studies that have examined the neuropathologic underpinnings of longitudinal WMH accumulation. Our study confirms that arteriolosclerosis is the most important pathologic correlate of WMH accumulation over time in aging. Additionally, we validated previous findings suggesting a link between CVD and AD neuropathology. Specifically, our results suggest that cerebral small-vessel disease is the main driver of white matter disruption, which has been shown to contribute to cognitive decline and dementia in old age. Cerebral large-vessel disease, however, may have a dual role, promoting both vascular brain injury as well as triggering mechanisms that lead to neurodegenerative changes of AD. Given the current limited treatments for latelife dementia, interventions throughout the entire life course to reduce both small-and large-vessel CVD are of high priority because reduction in CVD may ultimately reduce the incidence and prevalence of dementia in old age.
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